Osteogenic sarcoma in a patient with aplastic anemia.
Osteogenic sarcoma developed in a 14-year-old boy 13 years after he had partially recovered from chloramphenicol-induced aplastic anemia. A possible relationship is considered between aplastic anemia, chloramphenicol, testosterone, prednisone, and osteogenic sarcoma. Leukemia has been reported following chloramphenicol-induced aplastic anemia and liver tumors have been associated with testosterone therapy. Certain chemicals have caused osteogenic sarcoma in animals. Thus, we believe there are sufficient a priori reasons to question an etiologic relationship between the cause or treatment of aplastic anemia and osteogenic sarcoma.
D000293:Adolescent; D000741:Anemia, Aplastic / Q000139:chemically induced / Q000150:complications* / Q000188:drug therapy; D001859:Bone Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D002701:Chloramphenicol / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D012516:Osteosarcoma / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D011241:Prednisone / Q000009:adverse effects; D013739:Testosterone / Q000009:adverse effects
D013739:Testosterone; D002701:Chloramphenicol; D011241:Prednisone; D008727:Methotrexate